Louise Frisén

Louise Frisén

Auto-generated profile, based on publicly available information

Louise Frisén

Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in Adolescent Health, Medicine and Therapeutics
Verified
Journal Article
Open access
PDF file
RKRiittakerttu Kaltiala
Riittakerttu Kaltiala
HBHannah Bergman
Hannah Bergman
MTMarja Työläjärvi
Marja Työläjärvi
LFLouise Frisen
Louise Frisen
Increasing numbers of adolescents are seeking treatment at gender identity services in Western countries. An increasingly accepted treatment model that includes puberty suppression with gonadotropin-releasing hormone analogs starting during the early stages of puberty, cross-sex hormonal treatment starting at ~16 years of age and possibly surgical treatments in legal adulthood, is often indicated for adolescents with childhood gender dysphoria (GD) that intensifies during puberty. However, virtually nothing is known regarding adolescent-onset GD, its progression and factors that influence the completion of the developmental tasks of adolescence among young people with GD and/or transgender identity. Consolidation of identity development is a central developmental goal of adolescence, but we still do not know enough about how gender identity and gender variance actually evolve. Treatment-seeking adolescents with GD present with considerable psychiatric comorbidity. There is little research on how GD and/or transgender identity are associated with completion of developmental tasks of adolescence.

21 December 2020 in International Journal of Transgender Health
Verified
Journal Article
Open access
FFFelicitas Falck
Felicitas Falck
LFLouise Frisén
Louise Frisén
CDCecilia Dhejne
Cecilia Dhejne
GAGabriela Armuand
Gabriela Armuand
A sterilization requirement to change legal gender was removed from Swedish law in 2013, facilitating pregnancy in trans masculine individuals. The limited number of studies investigating pregnancy...

3 October 2021 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
Henrik FalhammarHenrik Falhammar
Henrik Falhammar
LFLouise Frisén
Louise Frisén
AHAngelica Lindén Hirschberg
Angelica Lindén Hirschberg
ANAgneta Nordenskjöld
Agneta Nordenskjöld
CACatarina Almqvist
Catarina Almqvist
Anna NordenstromAnna Nordenstrom
Anna Nordenstrom
Context: Low bone mineral density has been reported in individuals with congenital adrenal hyperplasia (CAH), but the prevalence of fractures is unclear. Objective: To study the prevalence of fractures in CAH. Design, Setting, and Participants: Patients with CAH (n = 714, all 21-hydroxylase deficiency) were compared with controls matched for sex and year and place of birth (n = 71 400). Data were derived by linking National Population-Based Registers. Main Outcome Measures: Number and type of fractures. Results: Mean age was 29.8 ± 18.4 years. Individuals with CAH had more fractures compared to controls [23.5% vs 16.1%, odds ratio (OR) 1.61, 95% CI 1.35-1.91], and this was found in both sexes (females: 19.6% vs 13.3%, OR 1.57, 95% CI 1.23-2.02; males: 28.7% vs 19.6%, OR 1.65, 95% CI 1.29-2.12). Fractures were significantly increased in patients born before the introduction of neonatal screening but not in those born afterwards. Any major fracture associated with osteoporosis (spine, forearm, hip, or shoulder) was increased in all individuals with CAH (9.8% vs 7.5%, OR 1.34, 95% CI 1.05-1.72). The highest prevalence of fractures was seen in SV phenotype and I172N genotype while nonclassic phenotype and I2 splice genotype did not show increased prevalence. A transport accident as a car occupant and fall on the same level were more common in patients with CAH, both sexes, than in controls. Conclusions: Patients with CAH had an increased prevalence of both any fracture and fractures associated with osteoporosis (both sexes) but not for patients neonatally screened. We conclude that fracture risk assessment and glucocorticoid optimization should be performed regularly.

27 July 2008 in Human Genetics
Verified
Journal Article
Closed access
PDF file
HTHanh T. T. Thai
Hanh T. T. Thai
CSCilla Söderhäll
Cilla Söderhäll
KLKristina Lagerstedt
Kristina Lagerstedt
MOMir Davood Omrani
Mir Davood Omrani
LFLouise Frisén
Louise Frisén
ANAgneta Nordenskjöld
Agneta Nordenskjöld